← back to search

Kotaro Shirakawa

Kyoto University Hospital · JP
Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, HIV/AIDS drug development and treatment, and SARS-CoV-2 detection and testing.
h-index
42
citations
12,148
works
110
NIH funding
primary concept
Medicine
email

Recent publications

Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy
Cytotherapy 2026cited by 0position: contributordoi
APOBEC3B Does Not Promote Tumor Progression in Tp53 Hemizygous Mice.
2025cited by 1position: contributordoi
APOBEC3B Does Not Promote Tumor Progression in Tp53 Hemizygous Mice
2024cited by 0position: contributordoi
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
2023cited by 273position: contributordoi
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.
2023cited by 122position: contributordoi
Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
2023cited by 11position: contributordoi
HTLV-1 bZIP factor impairs DNA mismatch repair system
Biochemical and Biophysical Research Communications 2023cited by 3position: contributordoi
Determination of the factors responsible for host tropism of SARS-CoV-2-related bat coronaviruses
2023cited by 0position: contributordoi
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Nature 2022cited by 1,160position: middledoi
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
2022cited by 937position: contributordoi
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
2022cited by 585position: contributordoi
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
2022cited by 525position: contributordoi
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
2022cited by 291position: contributordoi
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
2022cited by 238position: contributordoi
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
Cell Reports 2022cited by 145position: contributordoi
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
2022cited by 143position: contributordoi
The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant.
2022cited by 45position: contributordoi
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
2022cited by 35position: contributordoi
Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay.
2022cited by 26position: contributordoi
Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
2022cited by 25position: contributordoi
Virological characteristics of SARS-CoV-2 BA.2 variant
2022cited by 18position: contributordoi
Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
2022cited by 12position: contributordoi
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75
2022cited by 12position: contributordoi
ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells.
2022cited by 8position: contributordoi
Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.
2022cited by 7position: contributordoi
Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin.
2022cited by 5position: contributordoi
SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant
2022cited by 2position: contributordoi
Intratracheal trimerized nanobody cocktail protects against SARS-CoV-2 Omicron in mice
2022cited by 0position: contributordoi
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
2021cited by 1,109position: contributordoi
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
Nature 2021cited by 676position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Akifumi Takaori-Kondo · Kobe University13 papers (2019–2026)Akatsuki Saito · The University of Osaka13 papers (2021–2023) · 11 papers (2019–2026)Kei Sato · The University of Tokyo11 papers (2021–2023)Eric Verdin · Buck Institute for Research on Aging9 papers (2012–2016)So Nakagawa · National Institute of Genetics9 papers (2021–2023) · 6 papers (2021–2023)Yoshinobu Konishi · RIKEN Center for Integrative Medical Sciences6 papers (2021–2025)Kenzo Tokunaga · National Institute of Infectious Diseases6 papers (2021–2022)Shigeki Hirabayashi · Kyushu University5 papers (2019–2023) · 5 papers (2021–2023)Takamasa Ueno · Kagoshima University4 papers (2022–2022)Hyung W. Lim · Gladstone Institutes4 papers (2015–2016) · 4 papers (2021–2022)Anamaria Daniela Sarca · Kyoto University4 papers (2019–2021)Ravindra K. Gupta · University of Cambridge4 papers (2021–2022)Mélanie Ott · Chan Zuckerberg Initiative (United States)3 papers (2015–2016)Paúl Cárdenas · Imperial College London3 papers (2021–2022)Hideya Kawaji · RIKEN3 papers (2019–2021) · 3 papers (2021–2022)